Background: The female genital tract (FGT) microbiome may affect vaginal pH and other factors that influence drug movement into the vagina. We examined the relationship between the microbiome and antiretroviral concentrations in the FGT. Methods: Over one menstrual cycle, 20 human immunodeficiency virus (HIV)-infected women virologically suppressed on tenofovir (TFV) disoproxil fumarate/emtricitabine and ritonavir-boosted atazanavir (ATV) underwent serial paired cervicovaginal and plasma sampling for antiretroviral concentrations using high-performance liquid chromatography-tandem mass spectrometry. Analysis of 16S ribosomal RNA gene sequencing of cervicovaginal lavage clustered each participant visit into a unique microbiome community type (mCT). Results: Participants were predominantly African American (95%), with a median age of 38 years. Cervicovaginal lavage sequencing (n = 109) resulted in a low-diversity mCT dominated by Lactobacillus (n = 40), and intermediate-diversity (n = 28) and high-diversity (n = 41) mCTs with abundance of anaerobic taxa. In multivariable models, geometric mean FGT:plasma ratios varied significantly by mCT for all 3 drugs. For both ATV and TFV, FGT:plasma was significantly lower in participant visits with high- and low-diversity mCT groups (all P < .02). For emtricitabine, FGT:plasma was significantly lower in participant visits with low- vs intermediate-diversity mCT groups (P = .002). Conclusions: Certain FGT mCTs are associated with decreased FGT antiretroviral concentrations. These findings are relevant for optimizing antiretrovirals used for biomedical HIV prevention in women.
Background: The female genital tract (FGT) microbiome may affect vaginal pH and other factors that influence drug movement into the vagina. We examined the relationship between the microbiome and antiretroviral concentrations in the FGT. Methods: Over one menstrual cycle, 20 human immunodeficiency virus (HIV)-infectedwomen virologically suppressed on tenofovir (TFV) disoproxil fumarate/emtricitabine and ritonavir-boosted atazanavir (ATV) underwent serial paired cervicovaginal and plasma sampling for antiretroviral concentrations using high-performance liquid chromatography-tandem mass spectrometry. Analysis of 16S ribosomal RNA gene sequencing of cervicovaginal lavage clustered each participant visit into a unique microbiome community type (mCT). Results:Participants were predominantly African American (95%), with a median age of 38 years. Cervicovaginal lavage sequencing (n = 109) resulted in a low-diversity mCT dominated by Lactobacillus (n = 40), and intermediate-diversity (n = 28) and high-diversity (n = 41) mCTs with abundance of anaerobic taxa. In multivariable models, geometric mean FGT:plasma ratios varied significantly by mCT for all 3 drugs. For both ATV and TFV, FGT:plasma was significantly lower in participant visits with high- and low-diversity mCT groups (all P < .02). For emtricitabine, FGT:plasma was significantly lower in participant visits with low- vs intermediate-diversity mCT groups (P = .002). Conclusions: Certain FGT mCTs are associated with decreased FGT antiretroviral concentrations. These findings are relevant for optimizing antiretrovirals used for biomedical HIV prevention in women.
Authors: T Z DeSantis; P Hugenholtz; N Larsen; M Rojas; E L Brodie; K Keller; T Huber; D Dalevi; P Hu; G L Andersen Journal: Appl Environ Microbiol Date: 2006-07 Impact factor: 4.792
Authors: Katherine A Fethers; Christopher K Fairley; Jane S Hocking; Lyle C Gurrin; Catriona S Bradshaw Journal: Clin Infect Dis Date: 2008-12-01 Impact factor: 9.079
Authors: T W Chun; L Carruth; D Finzi; X Shen; J A DiGiuseppe; H Taylor; M Hermankova; K Chadwick; J Margolick; T C Quinn; Y H Kuo; R Brookmeyer; M A Zeiger; P Barditch-Crovo; R F Siliciano Journal: Nature Date: 1997-05-08 Impact factor: 49.962
Authors: Nichole R Klatt; Ryan Cheu; Kenzie Birse; Alexander S Zevin; Michelle Perner; Laura Noël-Romas; Anneke Grobler; Garrett Westmacott; Irene Y Xie; Jennifer Butler; Leila Mansoor; Lyle R McKinnon; Jo-Ann S Passmore; Quarraisha Abdool Karim; Salim S Abdool Karim; Adam D Burgener Journal: Science Date: 2017-06-02 Impact factor: 47.728
Authors: Scott Sherrill-Mix; Kaleigh Connors; Grace M Aldrovandi; Jason M Brenchley; Charles Boucher; Frederic D Bushman; Ronald G Collman; Satya Dandekar; Nichole R Klatt; Laurel A Lagenaur; Roger Paredes; Gilda Tachedjian; Jim A Turpin; Alan L Landay; Mimi Ghosh Journal: AIDS Res Hum Retroviruses Date: 2020-09-07 Impact factor: 2.205
Authors: Ignacio Rodríguez-Izquierdo; Daniel Sepúlveda-Crespo; Jose María Lasso; Salvador Resino; Ma Ángeles Muñoz-Fernández Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2022-01-12
Authors: Marie-Thérèse Nugeyre; Nicolas Tchitchek; Cindy Adapen; Claude Cannou; Vanessa Contreras; Fahd Benjelloun; Jacques Ravel; Roger Le Grand; Romain Marlin; Elisabeth Menu Journal: Front Cell Infect Microbiol Date: 2019-06-12 Impact factor: 5.293
Authors: Jennifer A Fulcher; Fan Li; Ryan R Cook; Sara Zabih; Alexander Louie; Hideaki Okochi; Nicole H Tobin; Monica Gandhi; Steven Shoptaw; Pamina M Gorbach; Grace M Aldrovandi Journal: Open Forum Infect Dis Date: 2019-10-29 Impact factor: 3.835
Authors: Cindy M Liu; Zoe R Packman; Alison G Abraham; David M Serwadda; Fred Nalugoda; Maliha Aziz; Jessica L Prodger; Rupert Kaul; Sarah Kalibbala; Ronald H Gray; Lance B Price; Thomas C Quinn; Aaron Ar Tobian; Steven J Reynolds Journal: Open Forum Infect Dis Date: 2019-07-12 Impact factor: 3.835